Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Sage Therapeutics secures NIH grant for Fragile X treatment
September 2013
SHARING OPTIONS:

CAMBRIDGE, Mass.Sage Therapeutics has received a grant from the U.S. National Institutes of Health (NIH) worth up to $10 million to develop a novel drug to treat patients with Fragile X Syndrome. The grant is one of three dispensed through the NIH Blueprint Neurotherapeutics Network, and will support day-to-day collaboration between Sage and the 15 organizations the Network is comprised of while advancing Sage's program through discovery and early clinical development. Sage Chief Scientific Officer Dr. Al Robichaud, is the principal investigator of the grant.  
 
"We are excited about the opportunity to apply cutting-edge science to the pursuit of novel treatments for Fragile X syndrome and other neurological disorders," said Dr. Rebecca Farkas, a program director at the National Institute of Neurological Disorders and Stroke, Office of Translational Research.  

 



Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.